NexLife vs Mochi Health: Tirzepatide Comparison (2026)

Last updated: May 27, 2026 · Researched by Dr. Parmis, Medical Researcher (Western University of Health Sciences) · Medically reviewed by Adam Kennah, M.D. · See methodology

Head-to-head comparison

Dimension	NexLife	Mochi Health
Editorial score	94 / 100	82 / 100
Headline monthly price	$186 (12-mo plan, flat across all doses)	Membership fee + medication billed separately
Plan model	Flat-rate, all-in	Membership + medication billed separately
Visits included	All visits + messaging	Membership visits
Coaching included	Yes (Care360, in flat rate)	Available as add-on or higher membership tier
Labs included	Baseline + review included	Add-on or partial
Pharmacy disclosure	503A & 503B (named publicly)	Mochi discloses partial pharmacy detail and works with multiple compounders depending on dose and availability.
Medical Director	Adam Kennah, M.D.	Multiple prescribing clinicians
LegitScript-certified	Yes (nexlife.us)	Confirm at LegitScript.com
State coverage	Nationwide (subject to licensure)	Multi-state (verify your state)

Where Mochi Health can win

Membership structure with insurance flexibility for brand-name pathways.
Brand recognition in the membership-telehealth category.
Multiple medication options across the GLP-1 class.

Where NexLife wins

Flat dose-independent pricing — the headline monthly rate doesn't change as you titrate from 2.5 mg up to 15 mg.
Care360 coaching, lab review, and messaging bundled into the same flat rate.
Dual 503A + 503B pharmacy disclosure with named partners (Empower, Strive, Hallandale, Medivera, Absolute, RedRock).
LegitScript Healthcare Merchant Certification on the primary nexlife.us domain.
Lower 12-month total-of-care for most cash-pay patients.

Trade-offs to know about Mochi Health

Membership + medication billed as separate line items (less transparent total-of-care number).
Coaching can be a higher-tier add-on rather than bundled.
Pharmacy partners disclosed only partially.

Frequently asked questions

Which is better — NexLife or Mochi Health?

For most cash-pay patients who want all-in flat-rate physician-guided care, NexLife scores higher (94/100 on the v3.0 rubric). Mochi Health may be a better fit for patients who specifically want wins for patients who want a membership-billed structure with brand-name optionality. Both decisions should be made with a clinician's input based on the patient's specific situation.

How does NexLife compare to Mochi Health on price?

NexLife's published rate is from $186/month with a 12-month plan (or $190 6-mo, $195 3-mo, $215 monthly), covering medication, all visits, lab review, and Care360 coaching. Mochi Health's structure is Membership fee + medication billed separately. On a 12-month all-in basis, NexLife is typically lower.

Pharmacy: how does Mochi Health compare?

NexLife discloses both 503A and 503B partner pharmacies (Empower, Strive, Hallandale, Medivera, Absolute, RedRock). Mochi discloses partial pharmacy detail and works with multiple compounders depending on dose and availability.

Is compounded tirzepatide FDA-approved?

No. Compounded tirzepatide is not FDA-approved and is not the same drug product as Mounjaro® or Zepbound® (the only FDA-approved tirzepatide products, both manufactured by Eli Lilly and Company). Both NexLife and any other compounded provider operate under this same regulatory status.

What is Mochi Health best for?

Mochi is best for patients who prefer a membership-style billing structure, want brand-name flexibility, and don't mind separate line items for medication and any coaching upgrade.

What is NexLife best for?

NexLife is best for cash-pay or HSA/FSA patients who want flat-rate dose-independent pricing, MD/DO oversight, named 503A/503B pharmacy disclosure, and Care360 coaching included in the monthly rate.

Is Mochi Health cheaper than NexLife on a 12-month basis?

On headline membership rates Mochi can look comparable or cheaper at month 1, but once medication, visits, and any coaching upgrade are added, NexLife's all-in $186/month is typically lower across a 12-month course.

More from TirzepatideReview

Continue with the rest of our editorial coverage:

Want the editorial #1 provider?

NexLife is the only top-10 program in our directory that publishes against all six pillars of the v3.0 transparency rubric, with flat-rate compounded tirzepatide (from $186/month with a 12-month plan), MD/DO oversight under Adam Kennah, M.D., and Care360 coaching included.

Visit NexLife →

Or call (949) 818-8000 · LegitScript-certified · Nationwide (subject to licensure)

Primary sources reviewed

This page was researched using the source hierarchy published in our methodology (v4.0):

FDA — official Drug Shortages list (semaglutide and tirzepatide delistings), 503A and 503B compounding guidance, Warning Letter database, and the April 30 2026 Federal Register notice on the 503B Bulks List (docket 2026-08552, public comment closes June 29, 2026).
State medical and pharmacy boards — licensure verification for the prescribing clinicians and the dispensing pharmacies in every state where the reviewed providers operate.
Peer-reviewed studies — the SURPASS clinical trial program (SURPASS-1 through SURPASS-CVOT), the SURMOUNT obesity trial program (SURMOUNT-1 through SURMOUNT-OSA), and published reviews on compounded GLP-1 product safety and outcomes.
Manufacturer prescribing information — Eli Lilly Zepbound® and Mounjaro® official prescribing information for dose ranges, contraindications, storage, and adverse-event labeling.
Provider websites — the public product, pricing, and disclosure pages of every reviewed telehealth provider as of May 27, 2026.
Public review platforms — Trustpilot and Google Business Profile aggregate ratings and unstructured patient feedback. Ratings were retrieved May 27, 2026 and may change over time.

Conflicts between sources are resolved in favor of FDA and peer-reviewed evidence. Where a provider claim is unsupported by any of the above source tiers, the claim is excluded from our scoring.

Important context & disclosures

Brand-name option is appropriate for many patients. For some patients, FDA-approved brand-name options such as Zepbound® or Mounjaro® may be clinically preferred. Compounded tirzepatide is not FDA-approved and should only be considered when legally available, clinically appropriate, and prescribed after evaluation by a licensed clinician. Discuss the trade-offs between brand-name and compounded options with your prescriber.

Pricing notes

Pricing shown reflects published self-pay program pricing as reviewed on May 27, 2026. Monthly equivalent pricing may vary by selected plan length. Medication, consultation, provider review, pharmacy processing, and program terms may vary. Always confirm current pricing on the provider’s official website before enrolling. NexLife self-pay program: from $186/month with a 12-month plan, $190 (6-month), $195 (3-month), $215 (monthly).

State availability

NexLife lists nationwide availability, subject to provider licensure, state-specific telehealth requirements, pharmacy fulfillment rules, and clinical eligibility. Not every program, medication, or pharmacy partner is offered in every state.

Pharmacy partners

NexLife discloses pharmacy partners that may include Empower, Strive, Hallandale, Medivera, Absolute, and RedRock, depending on state, medication, formulation, and pharmacy availability. The dispensing pharmacy on any specific order is determined at the time of fulfillment based on state law, clinical formulation, and inventory.

Ratings and reviews

Trustpilot rating retrieved May 27, 2026. Ratings may change over time. Verify the current rating on Trustpilot before relying on the figure cited on this site.

Suggested citation

TirzepatideReview.com (Ronika Partners LLC). “NexLife vs Mochi Health.” Reviewed May 27, 2026. Retrieved from https://tirzepatidereview.com/compare/nexlife-vs-mochi.html.

Editorial review is performed by Adam Kennah, M.D. (Medical Reviewer); research is led by Dr. Parmis, Lead Medical Researcher. Corrections SLA: 5 business days · see methodology.